Avacincaptad pegol  (Synonyms: Izervay)

Avacincaptad pegol (Izervay) is a selective inhibitor targeting complement component C5, and is a pegylated ribonucleic acid aptamer. Avacincaptad pegol inhibits the cleavage of C5 into pro-inflammatory C5a and C5b, which forms the membrane attack complex (C5b-9), thereby reducing inflammatory cell recruitment and retinal cell damage. Avacincaptad pegol can slow the growth of geographic atrophy (GA) lesions and reduce the risk of persistent vision loss. Avacincaptad pegol can be used in research of geographic atrophy associated with age-related macular degeneration (AMD) and has been approved by the FDA^[1][2].

Avacincaptad pegol exerts its complement inhibitory activity by specifically binding to complement component C5, inhibiting its cleavage into pro-inflammatory C5a and C5b, which forms the membrane attack complex (MAC), thus blocking the terminal steps of the complement cascade^[1].
Avacincaptad pegol can inhibit the damage to retinal pigment epithelial (RPE) cells caused by the complement activation product C5b-9, reduce lysosomal overload and the release of pro-inflammatory factors, maintain the stability of RPE cell function, and is associated with the improvement of pathological processes related to age-related macular degeneration (AMD)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In a male cynomolgus monkey (Macaca fascicularis) model, Avacincaptad pegol (1-1.5 mg/eye; intravitreal injection; once every 4 weeks for 4 doses) reduces the area of Ageographic atrophy in a sodium iodate-induced dry age-related macular degeneration model, but doesn't affect retinal or central macular thinning, nor does it induce choroidal neovascularization^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

52603 (Approximately)

1613641-69-2

Solid

White to off-white

Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, 5′-ether with RNA ((2′-deoxy-2′-fluoro)C-Gm-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)C-G-(2′-deoxy-2′-fluoro)C-Gm-Gm-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-Am-Gm-Gm-(2′-deoxy-2′-fluoro)C-G-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-Gm-Am-Gm-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-Gm-Am-Gm-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)U-A-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-Gm-(2′-deoxy-2′-fluoro)C-Gm-(3′→3′)-dT) 5′-[6-[[(2,3-dihydroxypropoxy)carbonyl]amino]hexyl hydrogen phosphate] (2:1)

[Avacincaptad pegol]

Room temperature in continental US; may vary elsewhere.

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Danzig CJ, et al. C5 inhibitor avacincaptad pegol treatment for geographic atrophy: A comprehensive review. Immunotherapy. 2024;16(12):779-790.  [Content Brief]

  [2]. Fujii R, et al. Intravitreal Administration of Avacincaptad Pegol in a Nonhuman Primate Model of Dry Age-Related Macular Degeneration. Pharmacol Res Perspect. 2025 Feb;13(1):e70052.  [Content Brief]